Evolution of Megakaryocyte Abnormalities in the Progression of Primary Myelofibrosis

The Mark Foundation for Cancer Research-Leukemia & Lymphoma Society Fellow (2021-Present)

Johanna Melo-Cardenas, PhD, St. Jude Children’s Research Hospital

Johanna Melo-Cardenas, PhD

Dr. Melo-Cardenas has been awarded a grant focused on studying alterations in large cells in the bone marrow called megakaryocytes, and exploring how changes in the bone marrow microenvironment contribute to disease progression in primary myelofibrosis, a blood cancer characterized by a buildup of fibrous tissue that impairs the bone marrow’s ability to produce normal blood cells.

Content courtesy of Leukemia & Lymphoma Society

published research

Melo-Cardenas J, Bezavada L, Crawford JC, Gurbuxani S, Cotton A, Kang G, Gossett JM, Marinaccio C, Weinberg RS, Hoffman R, Migliaccio AR, Zheng Y, Derecka M, Rinaldi CR, Crispino JD. IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood. 2022.